Based on P.R.E.M.I.U.M. (Pure, Reticulated, Elastic, Monophasic, Isotonic, Ultimate Ergonomics and Maximum Remanence) technology, this novel dermal filler fulfills all the required European standards, guaranteeing safety, durability and efficacy. Pluryal is not only ideal for wrinkles, but also for deep volumizing and augmentation treatments such as in the cheek, chin and/or lip areas.
According to Thomas Rappl, M.D., a plastic surgeon in Graz, Austria, “This is a unique dermal filler that has an optimal concentration of hyaluronic acid (23 mg/ mL) and a distinct structure, which explains the durability of the aesthetic results seen in my patients. Moreover, the product is packaged in a user-friendly ergonomic syringe for maximum comfort and control during the injection.”
Composed of a non-animal, pure hyaluronic acid, Pluryal is cross-linked with BDDE, a well-established and safe crosslinking agent. Its unique manufacturing method eliminates all residuals and compounds(i. e. proteins, endotoxins and BDDE) after the cross-linking process. Available in two strengths, Pluryal and Pluryal Volume have proven effective for most aesthetic indications, adding a simplistic approach to dermal filler treatments.
“Today’s aesthetic market is inundated with various dermal filler products that can be optimally used for specifi c target areas,” said Dr. Rappl. “The beauty of Pluryal is that the two strengths can address most of the indications encountered in your practice.It is much easier to work with two products for your aesthetic indications than a range of several different products.”
Dr. Rappl noted that the results achieved with Pluryal typically last from 6 to 12 months depending on the treated area and the individuals, which is comparable to the leading hyaluronic acid dermal fillers currently available on the market. “The significance of Pluryal products is that they possess very high viscoelastic properties making the results more natural and more durable than other hyaluronic acid dermal fi llers that do not have this high viscoelasticity,” he explained.
Adverse events associated with Pluryal are the same as any other dermal fi ller on the market and can include bruising, edema, erythema and swelling after injection, all of which typically dissipate 24 to 72 hours after treatment. However, according to Dr. Rappl, many of these adverse events can be kept to a minimum if the injector has an in depth knowledge of the facial anatomy and makes a proper analysis and evaluation of the treatment area.
“In my experience, the rate of injection and the use of topical anesthetics or regional blocks can help minimize bruising and hematomas at the injection site. Also, gently massaging and cooling the target area right after treatment may help to avoid swelling and edema,” Dr. Rappl shared.
These useful pearls are especially true in treatments where a replenishment of volume is the aesthetic goal. Dr. Rappl recommends the use of soft cannulas to considerably minimize typical adverse events and increase the patient’s comfort during treatment.
“Having one versatile dermal fi ller product (Pluryal) and one product for volumetric corrections (Pluryal Volume) makes it easier for physicians to manage their inventory – two products for all indications. In my opinion, Pluryal offers a simple, transparent and effective solution for aesthetic physicians and their patients,” Dr. Rappl concluded.
More information:
http://www.pluryal.com/